Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Evaluating ChatGPT's efficacy in assessing the safety of non-prescription medications and supplements in patients with kidney disease
9
Zitationen
9
Autoren
2024
Jahr
Abstract
ChatGPT's capabilities in evaluating the safety of non-prescription drugs and supplements for kidney disease patients are modest compared to established drug information resources. Neither ChatGPT-3.5 nor ChatGPT-4 can be currently recommended as reliable drug information sources for this demographic. The results highlight the need for further improvements in the model's accuracy and reliability in the medical domain.
Ähnliche Arbeiten
Explainable Artificial Intelligence (XAI): Concepts, taxonomies, opportunities and challenges toward responsible AI
2019 · 8.339 Zit.
Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead
2019 · 8.211 Zit.
High-performance medicine: the convergence of human and artificial intelligence
2018 · 7.614 Zit.
Proceedings of the 19th International Joint Conference on Artificial Intelligence
2005 · 5.776 Zit.
Peeking Inside the Black-Box: A Survey on Explainable Artificial Intelligence (XAI)
2018 · 5.478 Zit.